Company Encyclopedia
View More
name
DEZHAN HEALTHCARE
000813.SZ
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, and hydroxyurea tablets and colchicine tablet. It also involved in the provision of biological peptides, industrial hemp, and medical service business. The company was founded in 1980 and is based in Beijing, the People’s Republic of China.
3.159 T
000813.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking190/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-1.76%D
    • Profit Margin-22.98%E
    • Gross Margin58.11%B
  • Growth ScoreE
    • Revenue YoY-24.72%E
    • Net Profit YoY-398.04%E
    • Total Assets YoY-1.25%D
    • Net Assets YoY-3.84%D
  • Cash ScoreE
    • Cash Flow Margin-435.07%E
    • OCF YoY-24.72%E
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreA
    • Gearing Ratio5.18%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    DEZHAN HEALTHCARE: The relevant experiments for the IND application of WYY injection for stroke indications have been basically completed, and the clinical trial application is expected to be submitted in the second half of the year

    36Kr learned that DEZHAN HEALTHCARE stated on the interactive platform that the relevant experiments for the IND application of WYY injection for stroke indications have been basically completed, and the clinical trial application is expected to be submitted in the second half of the year

    36Kr·
    SZ
    000813
    +0.75%
    36Kr·
    SZ
    000813
    +0.75%

    Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

    Innovative drug concept stocks fluctuated and rose sharply, DEZHAN HEALTHCARE hit the limit up, Porton, JOINN, NHWA, Konruns, and SHANGHAI YIZHONG followed suit

    Zhitong·
    SH
    603127
    -0.07%
    HK
    06127
    +0.31%
    SZ
    002262
    +0.57%
    Zhitong·
    SH
    603127
    -0.07%
    HK
    06127
    +0.31%
    SZ
    002262
    +0.57%

    Innovative drug concept stocks collectively declined, Ausun Pharm hit the limit down

    Innovative drug concept stocks collectively fell, Ausun Pharm hit the limit down, SDKX dropped over 10%, Thalys, DEZHAN HEALTHCARE, and Hinova had significant declines

    Zhitong·
    SZ
    000813
    +0.75%
    SH
    688302
    +1.50%
    SH
    603229
    +0.52%
    Zhitong·
    SZ
    000813
    +0.75%
    SH
    688302
    +1.50%
    SH
    603229
    +0.52%

    DEZHAN HEALTHCARE: There has been no significant change in the internal and external operating environment

    DEZHAN HEALTHCARE issued a notice of unusual movements. As of the date of this announcement, there is no need to correct or supplement the information previously disclosed by the company; as of the date of this announcement, the company has not discovered any undisclosed significant information that has a substantial impact on the trading price of the company's stock due to recent public media reports or market rumors; the company's production and operation situation is normal, and as of the date of this announcement, there have been no significant changes in the internal and external operating environment

    Zhitong·
    SZ
    000813
    +0.75%
    Zhitong·
    SZ
    000813
    +0.75%

    DEZHAN HEALTHCARE: Expected net loss of 25 million to 50 million yuan in the first half of the year

    DEZHAN HEALTHCARE announced that it expects a net profit loss of 25 million to 50 million yuan in the first half of 2025, compared to a profit of 10.1526 million yuan in the same period last year, a year-on-year decline of 346.24%-592.48%

    Zhitong·
    SZ
    000813
    +0.75%
    Zhitong·
    SZ
    000813
    +0.75%
    © 2025 Longbridge｜Disclaimer